Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D Gothenburg, Sweden; Department of Chemistry and Molecular Biology, University of Gothenburg, Sweden.
Department of Chemistry and Molecular Biology, University of Gothenburg, Sweden.
Drug Discov Today. 2018 Jul;23(7):1426-1435. doi: 10.1016/j.drudis.2018.05.020. Epub 2018 May 18.
The rapid growth of antibiotic-resistant bacterial infections is of major concern for human health. Therefore, it is of great importance to characterize novel targets for the development of antibacterial drugs. One promising protein target is MraY (UDP-N-acetylmuramyl-pentapeptide: undecaprenyl phosphate N-acetylmuramyl-pentapeptide-1-phosphate transferase or MurNAc-1-P-transferase), which is essential for bacterial cell wall synthesis. Here, we summarize recent breakthroughs in structural studies of bacterial MraYs and the closely related human GPT (UDP-N-acetylglucosamine: dolichyl phosphate N-acetylglucosamine-1-phosphate transferase or GlcNAc-1-P-transferase). We present a detailed comparison of interaction modes with the natural product inhibitors tunicamycin and muraymycin D2. Finally, we speculate on possible routes to design an antibacterial agent in the form of a potent and selective inhibitor against MraY.
抗生素耐药菌感染的迅速增长对人类健康构成重大威胁。因此,确定新的抗菌药物靶标具有重要意义。一个很有前途的蛋白靶标是 MraY(UDP-N-乙酰基胞壁酰五肽:十一异戊烯焦磷酸 N-乙酰胞壁酰五肽-1-磷酸转移酶或 MurNAc-1-P-转移酶),它是细菌细胞壁合成所必需的。在这里,我们总结了细菌 MraY 和密切相关的人 GPT(UDP-N-乙酰葡萄糖胺:多萜醇磷酸 N-乙酰葡萄糖胺-1-磷酸转移酶或 GlcNAc-1-P-转移酶)的结构研究的最新突破。我们详细比较了与天然产物抑制剂衣霉素和 muraymycin D2 的相互作用模式。最后,我们推测了设计一种以 MraY 为靶标的高效、选择性抗菌剂的可能途径。